Literature DB >> 8094364

Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor alpha: a novel mechanism of action of sulphasalazine.

S M Greenfield1, A S Hamblin, Z S Shakoor, J P Teare, N A Punchard, R P Thompson.   

Abstract

The effects of the cytokine tumour necrosis factor alpha and the calcium ionophore A23187 upon CD11a, CD11b, CD11c and CD18 leucocyte membrane expression was analysed in whole blood using monoclonal antibodies and flow cytometry. Both agents significantly increased the density of CD11b/CD18 membrane expression on monocytes and granulocytes, but had no effects on adhesion molecule expression on lymphocytes. The effects of sulphasalazine, 5-aminosalicylic acid (5-ASA) and sulphapyridine upon adhesion molecule upregulation were then examined; 10(-3) and 10(-4) M sulphasalazine and 5-ASA significantly reduced tumour necrosis factor alpha induced CD11b/CD18 upregulation on monocytes and granulocytes but had no effects upon A23187 mediated upregulation. Sulphapyridine was inactive. These results suggest that sulphasalazine and 5-ASA may interfere with mechanisms of leucocyte recruitment in inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8094364      PMCID: PMC1373980          DOI: 10.1136/gut.34.2.252

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  26 in total

1.  A method of preparing blood leucocytes for flow cytometry which prevents upregulation of leucocyte integrins.

Authors:  A Hamblin; M Taylor; J Bernhagen; Z Shakoor; S Mayall; G Noble; D McCarthy
Journal:  J Immunol Methods       Date:  1992-02-05       Impact factor: 2.303

2.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

3.  Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease.

Authors:  S Schreiber; R P MacDermott; A Raedler; R Pinnau; M J Bertovich; G S Nash
Journal:  Gastroenterology       Date:  1991-10       Impact factor: 22.682

4.  Effect of sulphasalazine and its active metabolite, 5-amino-salicylic acid, on toxic oxygen metabolite production by neutrophils.

Authors:  J G Williams; M B Hallett
Journal:  Gut       Date:  1989-11       Impact factor: 23.059

5.  Inhibition of red cell membrane lipid peroxidation by sulphasalazine and 5-aminosalicylic acid.

Authors:  S M Greenfield; N A Punchard; R P Thompson
Journal:  Gut       Date:  1991-10       Impact factor: 23.059

6.  An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease.

Authors:  N Foley; C Lambert; M McNicol; N Johnson; G A Rook
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

7.  Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease.

Authors:  G Malizia; A Calabrese; M Cottone; M Raimondo; L K Trejdosiewicz; C J Smart; L Oliva; L Pagliaro
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

8.  Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

Authors:  S H Murch; V A Lamkin; M O Savage; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

9.  Sulfasalazine inhibits the binding of TNF alpha to its receptor.

Authors:  F Shanahan; A Niederlehner; N Carramanzana; P Anton
Journal:  Immunopharmacology       Date:  1990 Nov-Dec

10.  Tumour necrosis factor alpha in stool as a marker of intestinal inflammation.

Authors:  C P Braegger; S Nicholls; S H Murch; S Stephens; T T MacDonald
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

View more
  12 in total

Review 1.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

2.  Cytokine production in inflammatory bowel disease.

Authors:  J Satsangi; D P Jewell
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

3.  Sulphasalazine inhibits macrophage activation: inhibitory effects on inducible nitric oxide synthase expression, interleukin-12 production and major histocompatibility complex II expression.

Authors:  G Haskó; C Szabó; Z H Németh; E A Deitch
Journal:  Immunology       Date:  2001-08       Impact factor: 7.397

4.  Soluble adhesion molecules in inflammatory bowel disease.

Authors:  M G Goggins; J Goh; M A O'Connell; D G Weir; D Kelleher; N Mahmud
Journal:  Ir J Med Sci       Date:  2001 Apr-Jun       Impact factor: 1.568

5.  Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.

Authors:  G Frieri; R Giacomelli; M Pimpo; G Palumbo; A Passacantando; G Pantaleoni; R Caprilli
Journal:  Gut       Date:  2000-09       Impact factor: 23.059

6.  Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.

Authors:  F N Hussain; R A Ajjan; S A Riley
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

7.  Leucocyte adhesion deficiency presenting as a chronic ileocolitis.

Authors:  I D D'Agata; K Paradis; Z Chad; Y Bonny; E Seidman
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

8.  Antioxidant therapy with N-acetylcysteine plus mesalamine accelerates mucosal healing in a rodent model of colitis.

Authors:  Ali Siddiqui; Hanumantha Ancha; Dustin Tedesco; Stanley Lightfoot; Charles A Stewart; Richard F Harty
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

9.  Sulphasalazine in the treatment of children with chronic arthritis.

Authors:  J L Huang; L C Chen
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

Review 10.  Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.

Authors:  Nielsen Q Fernandez-Becker; Alan C Moss
Journal:  Drugs       Date:  2008       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.